Identity
Unverified · 0 matching sources · 2026-07-22No accepted supporting source is recorded for this field.
Agenova records Delfa as a browser and computer-use agents product from delfa.ai. No capability, pricing, or deployment field currently has publication-qualified Evidence; those claims remain Unknown.
Agenova verified this product identity, but accepted official evidence is currently insufficient for specific capability, pricing, integration, deployment, privacy, or enterprise-control claims. Unverified fields remain Unknown.
Delfa builds AI agents that automate patient recruitment for clinical trials, the single operational bottleneck behind much of trial cost and delay: with 22,000+ drug candidates in the pipeline but only about 5,000 new trials a year, more than a third of the cost comes down to finding, qualifying, and enrolling patients, still a manual funnel of Excel trackers, cold calls, and phone-collected histories. Delfa replaces that human bottleneck with agents trained on clinical trial documentation and guardrailed accordingly, which speak with patients in any language by phone, SMS, or chat to prescreen for medical eligibility, answer nuanced inclusion and exclusion questions, collect full medical histories (calls regularly run 20 minutes), book visits, and write directly into a site's CRM or CTMS. Quality is enforced heavily: every patient interaction is logged, reviewed, and scored across 20+ QA metrics, physicians audit outputs, and alerts fire in real time when something looks off. Because patients have opted in to trial contact, the use case is comparatively clean. Delfa already powers 50+ live trials with top site networks and has deployed production AI for J&J, Medtronic, and Exscientia. Reported outcomes include a migraine study site exceeding its enrollment target by 25% while saving 20 recruiter hours at an 11% lead-to-enrolled rate, and a vaccine trial where the agent matched human conversion. The company plans to build an AI-native CRM for patient recruitment on top of the voice wedge. $3.8M from Air Street.
No decision field has accepted public evidence yet.
0 of 8 decision fields supported. Evidence coverage is not a product score.
Known identity and product metadata appear below. The eight decision fields remain Unverified until accepted evidence supports them.
Request evidence →Documented product facts and Source-Backed claims do not establish execution quality or performance. Only publication-approved execution evidence can create an Execution-Verified state.
Documented product intelligence is not execution evidence or a performance claim. No publication-approved Execution-Verified edge appears unless its governed evidence passes.
No evidence-qualified capability edge is published for this profile. Provider-listed labels are not promoted as verified capabilities.
No accepted supporting source is recorded for this field.
No accepted supporting source is recorded for this field.
No accepted supporting source is recorded for this field.
No accepted supporting source is recorded for this field.
No accepted supporting source is recorded for this field.
No accepted supporting source is recorded for this field.
No accepted supporting source is recorded for this field.
No accepted supporting source is recorded for this field.
No accepted supporting source is recorded for this field.
These sources support only the fields named below. A missing source is reported as unknown, not as a negative product claim.